Y90 Radioembolization to the Prostate Gland: Proof of Concept in a Canine Model and Clinical Translation.

Abstract Purpose The feasibility, safety and absorbed dose distribution of prostate artery (PA) radioembolization (RE) was investigated in a canine model. Materials and Methods 14 male castrated beagles received dihydroandrosterone/estradiol to induce prostatic hyperplasia for the duration of the study. Each dog underwent fluoroscopic PA catheterization. 90Y microspheres (TheraSphere, Boston Scientific) was delivered to one prostatic-hemigland (dose escalation from 60-200Gy), with the contralateral side serving as the control. Assessments for adverse events were performed throughout the follow-up (CTCAE v 5.0). PET-MRI provided post-delivery confirmation of absorbed dose distribution. MRI was obtained pre-, and 3, 20, and 40 days post-RE. Tissue harvest of the prostate, rectum, bladder, urethra, penis, and neurovascular bundles occurred 60 days post-RE. Results All animals successfully underwent RE. PET-MRI demonstrated localaization to and good coverage of only the treated hemigland. No adverse events occurred. MRI showed a significant dose-dependent decrease in treated hemigland size at 40 days (25-60%, p Conclusion Prostate 90Y RE is safe and feasible in a canine model, with focal dose-dependent changes to the gland without inducing unwanted extra-postatic effects. These results suggest that investigation in nonoperative prostate cancer is warenteed..